tradingkey.logo

Amphastar Pharmaceuticals Inc

AMPH
查看詳細走勢圖
19.010USD
-0.520-2.66%
收盤 03/27, 16:00美東報價延遲15分鐘
825.15M總市值
9.06本益比TTM

Amphastar Pharmaceuticals Inc

19.010
-0.520-2.66%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.66%

5天

-2.51%

1月

-6.03%

6月

-29.20%

今年開始到現在

-29.01%

1年

-33.13%

查看詳細走勢圖

操作建議

Amphastar Pharmaceuticals Inc當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名37/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為29.00。中期看,股價處於下降通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Amphastar Pharmaceuticals Inc評分

相關信息

行業排名
37 / 157
全市場排名
117 / 4542
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Amphastar Pharmaceuticals Inc亮點

亮點風險
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
估值低估
公司最新PE估值9.06,處於3年歷史低位
機構加倉
最新機構持股33.97M股,環比增加0.05%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉542.00股

分析師目標

基於 7 分析師
買入
評級
29.000
目標均價
+48.49%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Amphastar Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Amphastar Pharmaceuticals Inc簡介

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
公司代碼AMPH
公司Amphastar Pharmaceuticals Inc
CEOZhang (Yongfeng Yongfeng)
網址https://amphastar.com/
KeyAI